CLVS Is Full of Upside Momentum CLVS 充满上升动力

After falling 55% from February 12 high $11.10 to March 5 low at 5.04, Clovis Oncology (CLVS) jump 0ver 56% today with 47 times average daily volume. The upside momentum looks very likely to continue because:

1. Data from randomized Phase 3 Ariel 4 study CLVS 's Rubraca significantly improves progression-free survival versus chemotherapy in patients with later-line ovarian cancer. The safety of Rubraca observed in the ARIEL4 study was highly consistent with both the U.S. and EU product labels.

2. There are 42% shorts on 86 million shares float, a perfect candidate for short squeeze.

3. Even before today's big move, Investors Business Daily's Acc/Dist rating was B-,Institutions have been buying. This rating could jump significantly after today's upside action. 

4. EPS this year is expected to increase by 41%. It's Price to Sales Ratio is only 3.56.

5. Bullish charts: CLVS gapped up through resistance $8, looks ready to challenge $10. $15 will be next if breaks through $10 . Its all time high price is $116.75 in 2015.

Clovis Oncology (CLVS 8.31), Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company distributes its products primarily through specialty pharmacies and distributors to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, and Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. The company was incorporated in 2009 and is headquartered in Boulder, Colorado.

从2月12日的高点11.10美元下跌35％至3月5日的低点5.04后，克洛维斯肿瘤学公司（CLVS）今天上涨超 56％，成交量为平均日两的47倍。上升势头很可能会持续，因为：

1.来自3期Ariel 4随机研究的数据与晚期化疗相比，CLVS的Rubraca与化疗相比可显着改善无进展生存期。ARIEL4研究中观察到的Rubraca安全性与美国和欧盟的产品标签高度一致。

2. 8600万股的流通量中有42％的空头，这是逼空的理想股票。

3.即使在今天大副上升之前，《投资者商业日报》的Acc / Dist评级为B-，机构一直在购买股票。在今天的上行行动之后，该评级可能会大幅上涨。

4.预计今年每股收益将增长41％。它的价格与销售比率仅为3.56。

5.牛势图表：CLVS突破阻力位8美元，看来准备挑战10美元。如果突破10美元，则接下来的目标将是$ 15。它的历史最高价格是2015年的116.75美元。

生物制药公司（Clovis Oncology，Inc. CLVS 8.31）致力于在美国，欧盟和国际上收购，开发和商业化抗癌药物。该公司提供Rubraca（rucaparib），一种多聚ADP-核糖聚合酶的口服小分子抑制剂，可用于复发性上皮性卵巢癌，输卵管癌或原发性腹膜癌以及转移性去势抵抗性前列腺癌。它还提供lucitanib，一种研究性血管生成抑制剂，可抑制血管内皮生长因子受体1至3（VEGFR 1-3），血小板衍生生长因子受体α和β（PDGFRa /）以及成纤维细胞生长因子受体1至3（ FGFR 1-3）； FAP-2286，一种靶向肽的放射性核素疗法和靶向成纤维细胞活化蛋白的显像剂。该公司主要通过专业药房和分销商向患者和医疗保健提供者分发其产品。 Clovis Oncology，Inc.与Pfizer Inc.，AstraZeneca UK Limited，Advenchen Laboratories LLC和3B Pharmaceuticals GmbH以及Bristol Myers Squibb Company拥有许可协议；该公司成立于2009年，总部位于科罗拉多州的博尔德。